Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Terapia inmunológica en asma
TL;DR: There is no evidence of influence on the incidence of asthma, possible beneficial effect on asthma exacerbations with antiinfluenzae vaccine, and some interesting points about pharmacogenetics are seen.
Book ChapterDOI
Omalizumab (Xolair) – Anti‐Immunoglobulin E Treatment in Allergic Diseases
Claus Kroegel,Martin Foerster +1 more
Journal ArticleDOI
Le Rôle de l’Omalizumab dans le Traitement de l’Asthme Allergique Grave
TL;DR: Un nouveau traitement anti-immunoglobuline E (anti-IgE) contre l’asthme, l‘omalizumab, a été approuvé au Canada.
Journal ArticleDOI
Adult asthma exacerbations in questions
David Montani,Arnaud Cavaillès,Laurent Bertoletti,A. Botelho,Alexis B. Cortot,Camille Taillé,Sylvain Marchand-Adam,D. Pinot,Christos Chouaid,Bruno Crestani,Gilles Garcia,Marc Humbert,J.-P. L’huillier,Antoine Magnan,Isabelle Tillie-Leblond,Pascal Chanez +15 more
TL;DR: A French working party critically review the international literature to revise the definition, pathophysiology, treatment and cost of exacerbations of adult asthma to help control asthma and prevent exacerbations.
Book ChapterDOI
Practical Considerations in the Management of Eosinophilic Asthma
Anurag Bhalla,Parameswaran Nair +1 more
TL;DR: Quantitative sputum cytometry is the most validated and sensitive test for diagnosis of eosinophilic asthma.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.